Ariana Announces New Release of its KEM® Multi-Objective Data Analysis and Decision Support Software with Enhanced Chemical Structure Analysis and Predictive Capabilities

Share Article

Ariana Pharma announced today that it has released a new version of its multi-objective data analysis and decision support software KEM®, bringing enhanced 2D visualization capabilities for identifying relations that link chemical structural features with multiple end points. In addition, the learning and prediction processes have been streamlined into a dedicated KEM Predict module for accurate prediction of end points. KEM is now also available through a command line interface, readily allowing the integration with a large variety of platforms.

Paris based Ariana Pharma announced today that it has released a new version of its multi-objective data analysis and decision support software KEM®, bringing enhanced 2D visualization capabilities for identifying relations that link chemical structural features with multiple end points. In addition, the learning and prediction processes have been streamlined into a dedicated KEM Predict module for accurate prediction of end points. KEM is now also available through a command line interface, readily allowing the integration with a large variety of platforms.

The new release of KEM® fully supports visualization of SMILES descriptors. Enhanced filtering capacities include substructure searches. Complex relations identified by KEM can be easily exported to a variety of formats including PDF. Improved molecular table include new tools for easy selection of molecules.

KEM Predict performs rule based learning and can be used from the command line to predict, with highly controlled accuracy, the values of a specified endpoint.

The new release of KEM brings significant additional benefits to its growing user community, which includes large and medium-size pharmaceuticals, as well as biotechnology companies.

About KEM®
KEM® (Knowledge Extraction and Management) is a proprietary decision support technology for rapid analysis of multi-parametric and multi-objective data. Deployed in pharmaceutical companies, KEM® has a unique ability to translate analysis of data from multiple sources into successful decisions for the optimisation of novel drug therapies. In clinical trials, KEM can fully characterise populations that are most responsive, as well as populations at risk, impacting the outcome of the trial as well as focusing the post launch marketing effort. Analysing safety data on both failed and marketed products, KEM is able to identify relations that link both molecular features and the results of early tests with the risk of adverse events.

About Ariana Pharma
Ariana™ Pharma delivers pioneering multi objectives decision support tools to dramatically accelerate and improve the discovery, development and safety of pharmaceutical products. Its KEM® knowledge extraction and management platform comprehensively mines data, including data other systems neglect, and helps scientists take simultaneous decisions involving multiple criteria and objectives. The Company has established a rapidly growing software business through collaboration and licensing agreements with some of the largest pharmaceutical and biotechnology companies. Ariana was founded in 2003 and is headquartered in Paris, France.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Mohammad Afshar
Ariana Pharma
+33 1 40 61 31 81
Email >
Visit website